Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27930763 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL7006678 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL29141523 | 0.97 | — | — | |
| SCHEMBL7006437 | 0.97 | — | — | |
| SCHEMBL8396732 | 0.97 | — | — | |
| Water SCHEMBL1325514 | 0.93 | — | — | |
| SCHEMBL29086542 | 0.93 | — | — | |
| Water SCHEMBL8722365 | 0.93 | — | — | |
| SCHEMBL29158521 | 0.93 | — | — | |
| SCHEMBL29053924 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109962289-B | Electrolyte composition and metal ion battery comprising same | 财团法人工业技术研究院 | 2022-03-11 | — | — | CN | claimed |
| CN-114019076-A | Method for simultaneously determining 5 components in compound hydroxypropyl theophylline dechlorinated hydroxyzine capsule | 苏州市药品检验检测研究中心 | 2022-02-08 | — | — | CN | claimed |
| CN-111051302-A | As pure 5-HT6Fluoropiperidine compounds as receptor antagonists | 苏文生命科学有限公司 | 2020-04-21 | — | — | CN | claimed |
| US-10587009-B2 | Electrolyte composition and metal-ion battery employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-03-10 | — | — | US | claimed |
| US-10367227-B2 | Electrolyte composition and metal-ion battery employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-07-30 | — | — | US | claimed |
| US-20190198929-A1 | ELECTROLYTE COMPOSITION AND METAL-ION BATTERY EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-06-27 | — | — | US | claimed |
| CN-106029671-B | Tricyclic triazolic compounds | 埃斯特维博士实验室股份有限公司 | 2018-10-12 | — | — | CN | claimed |
| US-20180219257-A1 | ALUMINUM-ION BATTERY | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-08-02 | — | — | US | claimed |
| US-20170358815-A1 | ELECTROLYTE COMPOSITION AND METAL-ION BATTERY EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-12-14 | — | — | US | claimed |
| CN-102898397-B | Synthesis method of (4aR,10bR)-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazine-9-ol substance and hydrochloride thereof | JIANGSU HUAYI TECHNOLOGY CO LTD | 2014-12-10 | — | — | CN | claimed |
| CN-102898397-A | Synthesis method of (4aR,10bR)-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazine-9-ol substance and hydrochloride thereof | JIANGSU HUAYI TECHNOLOGY CO LTD | 2013-01-30 | — | — | CN | claimed |
| CN-120131941-A | Overactivated dendritic cells can achieve durable anti-tumor immunity based on adoptive cell transfer | 儿童医学中心公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-112384505-B | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120025279-A | Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 | 格雷沃尔夫治疗有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-115137839-B | Targeting-co-loading hydrophilic/hydrophobic drug ferritin cage nano-carrier and application thereof | 南京纳么美科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-1028527-C | Process for preparing coumarin derivatives | SANKYO CO (JP) | 1995-05-24 | — | — | CN | disclosed |
| CN-1049662-A | Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder | SANKYO CO (JP) | 1991-03-06 | — | — | CN | disclosed |
| CN-1034918-A | Chemical compound | ICI PLC (GB) | 1989-08-23 | — | — | CN | disclosed |
| US-4758661-A | Chiral synthesis of (+)-trans-1a,2,3,4a,5,6-hexahydro-9-hydroxy-4-propyl-4H-naphth[1,2-b]-1,4-oxazine | MERCK & CO., INC. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0251547-A2 | Chiral synthesis of (+)-trans-la-2,3,4A, 5,6-hexahydro-9-hydroxy-4-propyl-4H-naphth-(1,2-B)-1,4-oxazine | MERCK & CO. INC. (US) | 1988-01-07 | — | — | EP | disclosed |